Cases reported "Eczema, Dyshidrotic"

Filter by keywords:



Filtering documents. Please wait...

1/10. Low-dose oral methotrexate treatment for recalcitrant palmoplantar pompholyx.

    We describe 5 patients with severe pompholyx who did not respond to conventional therapy or who had debilitating side effects from corticosteroids. Low-dose methotrexate was added to their treatment regimens and led to significant improvement or clearing with a favorable side-effect profile. In all 5 patients the need for oral corticosteroid therapy was substantially decreased or eliminated, thus decreasing potential corticosteroid-induced morbidity. In this uncontrolled series of patients with recalcitrant palmoplantar pompholyx, methotrexate was an effective treatment and acted as a steroid-sparing agent.
- - - - - - - - - -
ranking = 1
keywords = pompholyx, palmoplantar
(Clic here for more details about this article)

2/10. Complete remission of refractory dyshidrotic eczema with the use of radiation therapy.

    Dyshidrotic eczema is a chronic, enigmatic condition that usually affects the hands and feet. Modern-technique radiation therapy using megavoltage equipment for the treatment of dyshidrotic eczema has not been described in the literature before. A dramatic clinical response to low-dose external beam radiation therapy was observed in a patient refractory to multiple forms of topical and systemic agents. Complete resolution of this severe presentation of dyshidrosis occurred within 1 month following therapy, with a durable response at 6 months. Withdrawal of oral steroids, without flare of disease, was possible after 6 weeks, with the patient remaining free of medication at the 6-month interval. Complete remission of severe dyshidrotic eczema is achievable using low-dose external beam megavoltage therapy in situations where other forms of conventional therapies have failed. Lasting remission may allow for the complete withdrawal of oral or topical agents, which may become harmful with chronic use.
- - - - - - - - - -
ranking = 1.27746930914
keywords = dyshidrotic, eczema
(Clic here for more details about this article)

3/10. Resolution of dyshidrotic dermatitis of the hand after treatment with continuous positive airway pressure for obstructive sleep apnea.

    eczema of the palm and obstructive sleep apnea (OSA) are common disorders. Proinflammatory cytokines and cell adhesion molecules are elevated in both of these disorders. We describe an unusual patient with OSA who had recurrent free remission of dermatitis after treatment with continuous positive airway pressure. We speculate that the resolution of the patient's skin condition may reflect the effects of increased tissue oxygenation during sleep, reduced sleep fragmentation, and/or a reduction in sympathetic tone associated with successful sleep apnea treatment.
- - - - - - - - - -
ranking = 0.84656136774779
keywords = dyshidrotic
(Clic here for more details about this article)

4/10. Dyshidrotic-like spongiotic dermatitis after intravenous immunoglobulin therapy.

    Intravenous immunoglobulin (IVIG) therapy has been used to treat a variety of immune mediated disorders. Cutaneous reactions to IVIG are rare and have only been anecdotally described. We describe three cases with dyshidrotic-like biopsy proven spongiotic dermatitis after administration of IVIG. These three cases may highlight an uncommon and rarely reported side effect of IVIG.
- - - - - - - - - -
ranking = 0.21164034193695
keywords = dyshidrotic
(Clic here for more details about this article)

5/10. Photoinduced pompholyx: a report of 5 cases.

    We describe 5 patients whose histories and investigation findings point toward a diagnosis of photo-induced hand pompholyx, a previously unreported condition. Several factors have been associated with the exacerbation of pompholyx, but no direct relationship with sunlight exposure has been reported.
- - - - - - - - - -
ranking = 0.99986573550403
keywords = pompholyx
(Clic here for more details about this article)

6/10. Annular pompholyx.

    The common manifestation of pompholyx is easily recognized by the clinician. Morphologic variants are known in which the predominant lesions are pustules or desquamation with or without erythema. A patient is described herein whose eruption was composed mainly of arciform, annular, and target-like vesicles. Pompholyx (bubble) is a preferred term because "dyshidrosis" denotes a dysfunction of sweating, which does not occur in this condition. The causes of this eruption have not been determined, but it is likely that a certain genetic predisposition and multiple environmental factors are responsible. Pompholyx should be considered in the differential diagnosis of eruptions with annular pattern.
- - - - - - - - - -
ranking = 0.83322144625336
keywords = pompholyx
(Clic here for more details about this article)

7/10. Linear IgA disease with haemorrhagic pompholyx and dapsone-induced neutropenia.

    A case of haemorrhagic pompholyx occurring in a 29-year-old man with linear IgA disease is described. There were several features in our patient that are usually seen in chronic bullous disease of childhood. Treatment with dapsone cleared the eruption but induced a progressive yet reversible neutropenia.
- - - - - - - - - -
ranking = 0.83322144625336
keywords = pompholyx
(Clic here for more details about this article)

8/10. Treatment of pompholyx due to nickel allergy with chelating agents.

    Ingestion of nickel is important for the chronicity of hand eczema in nickel-sensitive patients. We have tried the effect of chelating agents. Diethyldithiocarbamate (DDC) and tetraethyl thiuramdisulfide (TETD) have proved effective in the treatment of nickel carbonyl poisoning. A 66-year-old woman suffering from severe nickel dermatitis has been treated in three periods, first with DDC 100 mg Q. I. D. for 20 days, and later with TETD 100 mg T. I. D. for two periods. An improvement has been observed in all three experiments.
- - - - - - - - - -
ranking = 0.66766676521959
keywords = pompholyx, eczema
(Clic here for more details about this article)

9/10. Ipsilateral post-cast hypertrichosis and dyshidrotic dermatitis.

    Post-cast hypertrichosis and dyshidrotic dermatitis are not uncommon separately. Yet, the simultaneous occurrence of both conditions in an individual is rare. A patient with both localized hypertrichosis and ipsilateral dyshidrotic dermatitis following multiple fractures and cast application is reported. The clinical presentation, management, spontaneous resolution, and/or response to therapy of post-cast hypertrichosis and dyshidrotic dermatitis that occurred concurrently in an individual were similar to that described when these conditions occur independently. The acquired conditions that may be associated with localized hypertrichosis are summarized and the postulated mechanisms of pathogenesis for dyshidrotic dermatitis are reviewed. The diagnosis of post-cast hypertrichosis in this patient was suspected based upon the distribution and temporal association of the hypertrichosis to the location and placement of his cast, and confirmed by excluding other causes of acquired localized hypertrichosis. Also, the possibility that in this individual either the trauma to his bones, the cast on his arm, or both had an etiologic role in promoting the development of dyshidrotic dermatitis is suggested.
- - - - - - - - - -
ranking = 1.9047630774325
keywords = dyshidrotic
(Clic here for more details about this article)

10/10. Contact allergy to 8-methoxypsoralen.

    A 36-year-old female patient was treated with PUVA for dyshidrotic eczema that had not shown sufficient response to topical therapy over the previous months. puva therapy caused acute aggravation of the eczema. Patch testing demonstrated Type IV sensitization to 8-methoxypsoralen in Meladinine solution.
- - - - - - - - - -
ranking = 0.21381955837076
keywords = dyshidrotic, eczema
(Clic here for more details about this article)
| Next ->


Leave a message about 'Eczema, Dyshidrotic'


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.